What oral medications are recommended for managing valvular heart disease and its common comorbidities?

Oral Medications for Valvular Heart Disease

The primary oral medications for valvular heart disease are anticoagulants for specific indications—particularly vitamin K antagonists (VKAs) for mechanical valves and rheumatic mitral stenosis with atrial fibrillation, and either VKAs or NOACs for native valve disease with atrial fibrillation based on CHA₂DS₂-VASc score—while no disease-modifying drugs exist for the valve lesions themselves. 1

Anticoagulation: The Core Medical Therapy

For Atrial Fibrillation with Native Valve Disease

NOACs are the preferred anticoagulant for most patients with AF and native valvular heart disease (excluding rheumatic mitral stenosis), offering similar efficacy to warfarin with reduced intracranial hemorrhage risk. 1 The decision to anticoagulate should follow the CHA₂DS₂-VASc scoring system through shared decision-making. 1

• NOACs reduce stroke/systemic embolism by 30% (OR 0.70), myocardial infarction by 30% (OR 0.70), and intracranial hemorrhage by 54% (OR 0.46) compared to warfarin in valvular heart disease patients 2
• Among NOACs, edoxaban 30 mg shows the lowest major bleeding risk, while rivaroxaban demonstrates increased intracranial hemorrhage and major bleeding compared to other NOACs 2

Critical Exceptions Requiring VKAs

Two absolute indications mandate VKA therapy over NOACs:

1. Rheumatic mitral stenosis with AF - VKA is the only recommended anticoagulant (Class I, Level C-EO) 1
2. Mechanical prosthetic valves - VKAs are mandatory for life; NOACs are contraindicated (Class III Harm, Level B-R) 1, 3

The RE-ALIGN trial definitively showed harm with dabigatran in mechanical valves, and anti-Xa NOACs remain untested and not recommended in this population. 3

Bioprosthetic Valves

For bioprosthetic valves >3 months post-implantation with AF, NOACs are acceptable alternatives to VKAs based on CHA₂DS₂-VASc score (Class I, Level A). 1

• In the early post-operative period (≤3 months after surgical or transcatheter bioprosthetic valve replacement), VKA anticoagulation is reasonable (Class IIa, Level B-NR) 1
• After 3 months, if AF persists, transition to NOAC is appropriate 4

Target INR Ranges for VKA Therapy

When VKAs are indicated, specific INR targets optimize the balance between thromboembolism and bleeding:

• Mechanical aortic valve (current-generation, no risk factors): INR 2.5 (range 2.0-3.0) 3
• Mechanical aortic valve with risk factors (AF, prior thromboembolism, LV dysfunction, hypercoagulable state): INR 3.0 (range 2.5-3.5) 3
• Mechanical mitral valve or older-generation mechanical valves: INR 3.0 (range 2.5-3.5) 3

Medications That Do NOT Treat Valve Disease Itself

There are no FDA-approved medications that modify the progression of structural valve disease. 5, 6 This is a critical pitfall—clinicians should not prescribe drugs expecting to slow aortic stenosis progression or reduce primary mitral regurgitation severity.

Symptomatic Management Only

• Diuretics for volume overload and symptom control in regurgitant lesions 5
• Rate/rhythm control for AF in mitral stenosis patients 5
• Antihypertensive therapy for aortic stenosis/regurgitation patients with hypertension 5

Heart Failure Comorbidity

For secondary (functional) mitral or tricuspid regurgitation, guideline-directed medical therapy for heart failure is appropriate as these are consequences of ventricular dysfunction rather than primary valve pathology. 1, 5

Antiplatelet Therapy: Limited Role

Aspirin alone is NOT recommended for stroke prevention in valvular heart disease without another indication. 7

Specific scenarios where antiplatelet therapy applies:

• Mitral annular calcification with prior systemic embolism/stroke: aspirin (Grade 1B) 7
• Aortic valve disease with prior ischemic stroke: aspirin (Grade 2C) 7
• Bioprosthetic valves without AF: aspirin (Grade 1B) 7

Common Pitfalls to Avoid

1. Never use NOACs in mechanical valves—this is contraindicated and harmful 1, 3
2. Do not prescribe ACE inhibitors, statins, or other drugs expecting to slow aortic stenosis—no evidence supports disease modification 6
3. Avoid rivaroxaban as first-line NOAC in valvular AF given increased bleeding risk compared to other NOACs 2
4. Do not withhold NOACs in patients with mild-moderate aortic stenosis, aortic regurgitation, or mitral regurgitation—these are NOT contraindications 1, 8
5. Rivaroxaban 10 mg plus aspirin post-TAVR is contraindicated without other indications for anticoagulation 3

Algorithm for Anticoagulation Decision-Making

Step 1: Identify valve type

• Mechanical → VKA (lifelong)
• Rheumatic mitral stenosis → VKA if AF present
• Native valve or bioprosthetic >3 months → Proceed to Step 2

Step 2: Assess for AF

• No AF → No anticoagulation for valve disease alone
• AF present → Calculate CHA₂DS₂-VASc score

Step 3: If CHA₂DS₂-VASc ≥2 (men) or ≥3 (women)

• Native valve disease or bioprosthetic >3 months → NOAC preferred
• Rheumatic mitral stenosis → VKA only
• Mechanical valve → VKA only